Diabeloop announced today that study data support the use of its DBLG1 hybrid closed-loop automated insulin delivery system.
Paris-based Diabeloop’s real-life German cohort data, presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona, show a constant improvement in time in range (70-180 mg/dL) combined with a significant reduction of hypoglycemia.
Get the full story at our sister site, Drug Delivery Business News.